| Grant of Share Options | 05-May-2026 | 07:00 | RNS |
| Q1 2026 Trading Update | 01-May-2026 | 07:00 | RNS |
| Total Voting Rights | 30-Apr-2026 | 07:01 | RNS |
| Enrollment in Phase II Clinical Trial for ACCRUFeR | 27-Apr-2026 | 07:00 | RNS |
| Audited results for year ended 31 December 2025 | 09-Apr-2026 | 12:30 | RNS |
| Total Voting Rights | 31-Mar-2026 | 07:03 | RNS |
| EMA approves extension - to include adolescents | 31-Mar-2026 | 07:00 | RNS |
| Chinese NMPA Accepts MAA Submission for ACCRUFeR... | 03-Mar-2026 | 07:00 | RNS |
| Total Voting Rights | 27-Feb-2026 | 07:00 | RNS |
| FDA Grants additional Exclusivity for ACCRUFeR | 09-Feb-2026 | 07:00 | RNS |
| Total Voting Rights | 30-Jan-2026 | 07:05 | RNS |
| Approval for ACCRUFeR in China expected in Q1 2026 | 30-Jan-2026 | 07:00 | RNS |
| Q4 2025 Trading Update | 21-Jan-2026 | 07:00 | RNS |
| Block listing 6 Monthly Return | 02-Jan-2026 | 11:06 | RNS |
| Total Voting Rights | 02-Jan-2026 | 07:00 | RNS |
| Currency | UK Pounds |
| Share Price | 7.00p |
| Change Today | 0.000p |
| % Change | 0.00 % |
| 52 Week High | 12.20 |
| 52 Week Low | 2.35 |
| Volume | 906,796 |
| Shares Issued | 1,068.42m |
| Market Cap | £74.79m |
| Beta | 0.03 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| Strong Buy | 1 |
| Buy | 1 |
| Neutral | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 2 |

| No dividends found |
| Time | Volume / Share Price |
| 14:47 | 14 @ 7.10p |
| 14:47 | 6,898 @ 7.10p |
| 14:46 | 8,835 @ 7.10p |
| 14:46 | 986 @ 7.10p |
| 14:46 | 14 @ 7.10p |
You are here: research